论文部分内容阅读
ＣＹＦＲＡ２１－１是从肺癌患者血清中发现的角蛋白１９片段（ｃｙｔｏｋｅｒａｔｉｎ１９ｆｒａｇｍｅｎｔ）。本文７０例原发性支气管肺癌测定值为８．９６±１４．４８μｇ／Ｌ，其中鳞癌最高为２３．０１±６０．９０μｇ／Ｌ。如以法国ＣＩＳ公司提供的阳性判定值３．３μｇ／Ｌ为界，则ＣＹＦＲＡ２１－１对肺癌的检出率为５２．９％，其中鳞癌达５９．３％，２１例肺良性疾患ＣＹＦＲＡ２１－１测定均为阴性，特异性为１００％，表明ＣＹＦＲＡ２１－１对肺癌检测有较高的特异性，而ＳＣＣ对肺鳞癌的检出率仅４４．４％，特异性为９０．４％。ＣＹＦＲＡ２１－１与ＳＣＣ联合检测可使肺鳞癌的阳性率提高到７０．４％，但特异性下降至９０．４％，ＣＹＦＲＡ２１－１对肺癌的检测有较高的特异性和检出率，优于常用的ＣＥＡ、ＳＣＣ等肿瘤标志物，同时对肺癌的临床分期也有一定的参考价值。
CYFRA21-1 is a cytokeratin 19 fragment found in the serum of lung cancer patients. The determination of 70 cases of primary bronchogenic lung cancer was 8.96±14.48μg/L. The highest squamous cell carcinoma was 23.01±60.90μg/L. For example, the positive judgment value provided by French CIS company is 3.3μg/L. The detection rate of CYFRA21-1 for lung cancer is 52.9%, of which squamous cell carcinoma is 59.3%, and 21 cases of lung benign disease CYFRA21- 1 The assay was negative, with a specificity of 100%, indicating that CYFRA21-1 had higher specificity for detection of lung cancer, while the detection rate of SCC for lung squamous cell carcinoma was only 44.4% and specificity was 90.4%. The combined detection of CYFRA21-1 and SCC increased the positive rate of squamous cell carcinoma to 70.4%, but the specificity decreased to 90.4%. CYFRA21-1 has higher specificity and detection rate for the detection of lung cancer. It is better than commonly used tumor markers such as CEA and SCC, and also has certain reference value for the clinical stage of lung cancer.